Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to ...

Investors are running into Viking Therapeutics (NASDAQ: VKTX) this week after an incident of drug-induced liver injury pushed ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday ...

Pfizer Inc. (NYSE:PFE – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the company, Marketbeat reports.

Pfizer (NYSE:PFE) recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...